Insulin lispro (Lyumjev)

Peptide

Also known as LY900014

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Diabetes mellitus requiring insulin therapy
Product first approved 2020digitalpr.jp
EU
  • Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above
Product first approved 2020EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (8)
Type 1 Diabetes
NCT03952130 · Eli Lilly and Company
2019-05-29 – 2022-01-10 · Type 1 Diabetes Mellitus
What this study did
NCT03433677 · Eli Lilly and Company
2018-02-21 – 2018-09-04 · Diabetes Type 1
What this study did
Type 2 Diabetes
Phase 2 (3)
Type 1 Diabetes
NCT06021158 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2023-12-20 – 2024-12 · Diabetes Mellitus, Type 1, Type 1 Diabetes
What this study did
NCT04585776 · Eli Lilly and Company
2020-10-30 – 2021-05-27 · Type 1 Diabetes
What this study did
NCT03760640 · Eli Lilly and Company
2019-02-18 – 2019-10-07 · Type1 Diabetes Mellitus
What this study did
Phase 1/2 (1)
Type 1 Diabetes
NCT06854861 · St. Olavs Hospital
2025-04-01 – 2026-06-01 · Type 1 Diabetes
What this study did
Phase 1 (25)
Type 1 Diabetes
NCT07341373 · Portal Diabetes, Inc.
2026-02-10 – 2026-09-30 · Type 1 Diabetes
What this study did
NCT05262387 · Eli Lilly and Company
2022-02-14 – 2023-03-07 · Diabetes Mellitus, Type 1
What this study did
NCT04276207 · Eli Lilly and Company
2020-02-25 – 2020-08-10 · Diabetes Mellitus, Type 1
What this study did
NCT03465878 · Eli Lilly and Company
2018-03-26 – 2019-11-14 · Type 1 Diabetes Mellitus
What this study did
NCT03449433 · Eli Lilly and Company
2018-03-15 – 2018-08-14 · Diabetes Mellitus, Type 1
What this study did
NCT03407118 · Eli Lilly and Company
2018-02-17 – 2018-07-12 · Diabetes Mellitus, Type 1
What this study did
NCT03341299 · Eli Lilly and Company
2017-11-13 – 2018-04-03 · Diabetes Mellitus, Type 1
What this study did
NCT03166124 · Eli Lilly and Company
2017-05-24 – 2017-11-18 · Diabetes Mellitus, Type 1
What this study did
NCT03056456 · Eli Lilly and Company
2017-02-23 – 2017-06-19 · Diabetes Mellitus, Type 1
What this study did
NCT02703324 · Eli Lilly and Company
2016-03 – 2016-08 · Diabetes Mellitus, Type 1
What this study did
NCT02703350 · Eli Lilly and Company
2016-03 – 2016-07 · Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT03341312 · Eli Lilly and Company
2017-11-13 – 2018-03-31 · Diabetes Mellitus, Type 2
What this study did
NCT03286751 · Eli Lilly and Company
2017-10-13 – 2018-02-06 · Diabetes Mellitus, Type 2
What this study did
NCT03305822 · Eli Lilly and Company
2017-10-11 – 2017-12-14 · Diabetes Mellitus, Type 2
What this study did
NCT03232983 · Eli Lilly and Company
2017-08-14 – 2017-11-09 · Diabetes Mellitus, Type 2
What this study did
NCT02703337 · Eli Lilly and Company
2016-03 – 2016-08 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT04049123 · Eli Lilly and Company
2019-11-18 – 2020-10-23 · Healthy
What this study did
NCT03616977 · Eli Lilly and Company
2018-08-03 – 2018-10-19 · Healthy
What this study did
NCT03334448 · Eli Lilly and Company
2017-12-04 – 2018-03-15 · Healthy
What this study did
NCT02942654 · Eli Lilly and Company
2016-11 – 2016-12 · Healthy
What this study did
NCT02770521 · Eli Lilly and Company
2016-05 – 2016-07 · Healthy
What this study did
NCT02752087 · Eli Lilly and Company
2016-04 – 2016-05 · Healthy
What this study did
NCT02636361 · Eli Lilly and Company
2015-12 – 2016-02 · Healthy
What this study did
NCT02525744 · Eli Lilly and Company
2015-08 – 2015-10 · Healthy
What this study did
NCT02317575 · Eli Lilly and Company
2015-01 – 2015-09 · Healthy Volunteers
What this study did
Phase 4 (1)
Type 2 Diabetes
NCT06370715 · Eli Lilly and Company
2024-04-18 – 2025-09-02 · Diabetes Mellitus, Type 2
What this study did
Early phase / not applicable (4)
Type 1 Diabetes
NCT06948760 · Mark D. DeBoer, MD, MSc., MCR
2025-07-23 – 2026-03-10 · Type 1 Diabetes
What this study did
NCT05325294 · Medtronic MiniMed, Inc.
2022-05-05 – 2024-01-03 · Type 1 Diabetes
What this study did
NCT05508061 · Inreda Diabetic B.V.
2022-10-19 – 2023-03-16 · Type 1 Diabetes
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
Type 1 Diabetes
NCT07090824 · Stanford University
2025-10-28 – 2026-05-29 · Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2/3 (1)
Type 1 Diabetes
NCT06046417 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2023-11-30 – 2025-06 · type1diabetes, Diabetes Mellitus, Type 1
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Insulin Lispro (Lyumjev): this drugApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin HumanApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
CadisegliatinPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.